

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1646jxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the present  
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective August 1, 2003  
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation  
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR  
NEWS 10 SEP 22 DIPPR file reloaded  
NEWS 11 DEC 08 INPADOC: Legal Status data reloaded  
NEWS 12 SEP 29 DISSABS now available on STN  
NEWS 13 OCT 10 PCTFULL: Two new display fields added  
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
NEWS 16 NOV 24 MSDS-CCOHS file reloaded  
NEWS 17 DEC 08 CABA reloaded with left truncation  
NEWS 18 DEC 08 IMS file names changed  
NEWS 19 DEC 09 Experimental property data collected by CAS now available in REGISTRY  
NEWS 20 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS  
NEWS 21 DEC 17 DGENE: Two new display fields added  
NEWS 22 DEC 18 BIOTECHNO no longer updated  
NEWS 23 DEC 19 CROPU no longer updated; subscriber discount no longer available  
NEWS 24 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS databases  
NEWS 25 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields  
NEWS 26 DEC 22 ABI-INFORM now available on STN  
  
NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may



**antibodies** have shown efficacy in decreasing disease activity. These data have provided a rationale for immunotherapy of Crohn's disease. Administration of anti-TNF **antibodies** to patients with Crohn's disease not responding to standard immunosuppressive treatment rapidly induced complete remissions, and healing of intestinal ulceration. A rapid reduction of circulating IL-6, CPR, and sPLA2 levels was observed in all patients, as well as a reduction of mucosal cells expressing RANTES and MIP-1. Short-term treatment with anti-TNF **antibodies** was not associated with significant toxicity, but results from long-term administration are still lacking. These data indicate that TNF is a pivotal and central inflammatory mediator in this disease. Further characterization of the precise mechanism of action of anti-TNF antibody therapy may further unravel the cause of immune dysregulation in Crohn's disease.

L3 ANSWER 2 OF 2 CANCERLIT on STN  
ACCESSION NUMBER: 97071010 CANCERLIT  
DOCUMENT NUMBER: 97071010 PubMed ID: 8913936  
TITLE: Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti-TNF therapy.  
AUTHOR: Stokkers P C; Camoglio L; van Deventer S J  
CORPORATE SOURCE: Laboratory for Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands.  
SOURCE: JOURNAL OF INFLAMMATION, (1995-96) 47 (1-2) 97-103. Ref: 54  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LANGUAGE: English  
FILE SEGMENT: MEDLINE; Priority Journals  
OTHER SOURCE: MEDLINE 97071010  
ENTRY MONTH: 199702  
ENTRY DATE: Entered STN: 19970305  
Last Updated on STN: 19970305

AB The inflammatory bowel diseases frequently require surgery because of intestinal complications. Animal models of inflammatory bowel disease, in particular those that histopathologically resemble Crohn's disease, are characterized by increased mucosal TNF production, and anti-TNF **antibodies** have shown efficacy in decreasing disease activity. These data have provided a rationale for immunotherapy of Crohn's disease. Administration of anti-TNF **antibodies** to patients with Crohn's disease not responding to standard immunosuppressive treatment rapidly induced complete remissions, and healing of intestinal ulceration. A rapid reduction of circulating IL-6, CPR, and sPLA2 levels was observed in all patients, as well as a reduction of mucosal cells expressing RANTES and MIP-1. Short-term treatment with anti-TNF **antibodies** was not associated with significant toxicity, but results from long-term administration are still lacking. These data indicate that TNF is a pivotal and central inflammatory mediator in this disease. Further characterization of the precise mechanism of action of anti-TNF antibody therapy may further unravel the cause of immune dysregulation in Crohn's disease.

=> d his

(FILE 'HOME' ENTERED AT 18:04:54 ON 22 DEC 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, CANCERLIT' ENTERED AT 18:05:19 ON 22 DEC 2003

L1 333675 S TNF OR TUMOR (W) NECROSIS (W) FACTOR  
L2 918 S (TNF OR TUMOR (W) NECROSIS (W) FACTOR) (W) ANTIBODIES

L3 2 S L2 (S) (MIP-1B OR RANTES)

=> s l1 S (fusion or conjugate) s chemokine?

MISSING OPERATOR L1 S

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s s l1 S (fusion or conjugate)

MISSING OPERATOR S L1

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 (s) (fusion? or conjugate?)

L4 3699 L1 (S) (FUSION? OR CONJUGATE?)

=> s l4 (s) chemokine?

L5 42 L4 (S) CHEMOKINE?

=> s l5 (s) antibodies

L6 5 L5 (S) ANTIBODIES

=> duplicate remove 16

DUPLICATE PREFERENCE IS 'EMBASE, CANCERLIT'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/ (N) :n

PROCESSING COMPLETED FOR L6

L7 3 DUPLICATE REMOVE L6 (2 DUPLICATES REMOVED)

=> d 17 1-

YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/ (N) :y

L7 ANSWER 1 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

AN 2003161017 EMBASE

TI Cytokine, chemokine, and costimulatory molecule modulation to enhance  
efficacy of HIV vaccines.

AU Ahlers J.D.; Belyakov I.M.; Berzofsky J.A.

CS J.A. Berzofsky, Molec. Immunogen./Vaccine Res. Sec., Metabolism Branch,  
National Cancer Institute, Building 10, Bethesda, MD 20892-1578, United  
States. jahlers@niaid.nih.gov

SO Current Molecular Medicine, (2003) 3/3 (285-301).

Refs: 206

ISSN: 1566-5240 CODEN: CMMUBP

CY Netherlands

DT Journal; General Review

FS 004 Microbiology

026 Immunology, Serology and Transplantation

030 Pharmacology

037 Drug Literature Index

039 Pharmacy

LA English

SL English

L7 ANSWER 2 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN DUPLICATE 1

AN 2001154626 EMBASE

TI Anti-TNF.alpha. therapy of rheumatoid arthritis: What have we learned?.

AU Feldmann M.; Maini R.N.

CS M. Feldmann, Kennedy Inst. of Rheumatology Div., Imperial College School  
of Medicine, 1 Aspenlea Road, London W6 8LH, United Kingdom.  
m.feldmann@ic.ac.uk

SO Annual Review of Immunology, (2001) 19/- (163-196).

Refs: 160

ISSN: 0732-0582 CODEN: ARIMDU

CY United States

DT Journal; General Review

FS 026 Immunology, Serology and Transplantation  
031 Arthritis and Rheumatism  
037 Drug Literature Index  
LA English  
SL English

L7 ANSWER 3 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN DUPLICATE 2

AN 1998362492 EMBASE  
TI Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture,  
firm adhesion, and activation under physiologic flow.  
AU Fong A.M.; Robinson L.A.; Steeber D.A.; Tedder T.F.; Yoshie O.; Imai T.;  
Patel D.D.  
CS D.D. Patel, Box 3258, 222 CARL Bldg., Duke University Medical Center,  
Durham, NC 27710, United States. patel003@mc.duke.edu  
SO Journal of Experimental Medicine, (19 Oct 1998) 188/8 (1413-1419).  
Refs: 28  
ISSN: 0022-1007 CODEN: JEMEAV  
CY United States  
DT Journal; Article  
FS 025 Hematology  
029 Clinical Biochemistry  
LA English  
SL English

=> d his

(FILE 'HOME' ENTERED AT 18:04:54 ON 22 DEC 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, CANCERLIT' ENTERED AT 18:05:19 ON  
22 DEC 2003

L1 333675 S TNF OR TUMOR (W) NECROSIS (W) FACTOR  
L2 918 S (TNF OR TUMOR (W) NECROSIS (W) FACTOR) (W) ANTIBODIES  
L3 2 S L2 (S) (MIP-1B OR RANTES)  
L4 3699 S L1 (S) (FUSION? OR CONJUGATE?)  
L5 42 S L4 (S) CHEMOKINE?  
L6 5 S L5 (S) ANTIBODIES  
L7 3 DUPLICATE REMOVE L6 (2 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	50.13	50.34

STN INTERNATIONAL LOGOFF AT 18:16:58 ON 22 DEC 2003